Latest Cost Reduction Initiatives News

The Star Entertainment Group has secured a US$390 million, three-year credit facility with WhiteHawk Capital Partners, fully refinancing its existing debt and unlocking approximately A$130 million in additional liquidity.

ImpediMed has secured A$15.2 million through a two-tranche placement and share purchase plan, alongside A$5 million in cost reductions, aiming for operating cashflow breakeven by H2 FY28.

AdNeo (ASX:AD1) delivered its first positive operating cash flow quarter since its 2025 transformation, driven by strong revenue growth across all divisions and a growing $8m tender pipeline. The company advances its AI-first strategy while managing costs and acquisitions.

Qoria Limited has increased its equity placement to US$100 million, backed by insiders, to support aggressive AI investment and integration with Aura. The combined group reports robust ARR growth and reiterates FY26 guidance amid ongoing merger preparations.

Coronado Global Resources (ASX: CRN) will hold its 2026 Annual General Meeting virtually on June 4, 2026, following a challenging 2025 marked by a $432 million net loss amid weak metallurgical coal prices and logistical constraints. The company reported operational improvements and liquidity support from Stanwell, while navigating leadership changes and ongoing risks.

Stanmore Resources defied a four-year low in metallurgical coal prices to deliver record saleable production and robust cash flow in 2025, while maintaining a strong safety record and advancing key development projects.

Botanix Pharmaceuticals has successfully renegotiated its API supply agreement, deferring significant purchases to later years and strengthening its financial position ahead of Sofdra's market rollout.

Air New Zealand has halted its full-year 2026 earnings guidance following a sharp spike in jet fuel prices triggered by Middle East conflict, introducing uncertainty into its financial outlook.

Spenda Limited has successfully raised $1.4 million through a private placement, supported by both new and existing sophisticated investors, including key directors. The funds will fuel the company’s commercialisation efforts and strengthen its working capital position.

Botanix Pharmaceuticals reports a surge in Sofdra sales driving revenue to $16.5 million, yet the company records a $33.2 million loss amid expanded marketing and operational costs. A $45 million capital raise aims to support growth and supply chain improvements.

VEEM Ltd posted a significant half-year loss of $19.5 million, driven by a 30% revenue decline and a $24.8 million impairment on gyro product development. Despite setbacks, new product launches and US defence market progress offer a hopeful outlook.

APA Group has reported robust half-year results, boosting its organic growth pipeline to nearly $3 billion and reaffirming its full-year guidance amid ongoing cost reductions and strategic divestments.